EXHIBIT 31.1

CERTIFICATION

I, David Aviezer, certify that:

1.

I have reviewed this quarterly report on Form 10-Q of Protalix
		BioTherapeutics, Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement
		of a material fact or omit to state a material fact necessary to make the
		statements made, in light of the circumstances under which such statements were
		made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial
		information included in this report, fairly present in all material respects
		the financial condition, results of operations and cash flows of the registrant
		as of, and for, the periods presented in this report;

4.

The registrants other certifying officer and I are responsible for
		establishing and maintaining disclosure controls and procedures (as defined in
		Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a)

Designed such disclosure controls and procedures, or caused such
		disclosure controls and procedures to be designed under our supervision, to
		ensure that material information relating to the registrant, including its
		consolidated subsidiaries, is made known to us by others within those entities,
		particularly during the period in which this report is being prepared;

b)

Evaluated the effectiveness of the registrants disclosure controls
		and procedures and presented in this report our conclusions about the
		effectiveness of the disclosure controls and procedures, as of the end of the
		period covered by this report based on such evaluation; and

c)

Disclosed in this report any change in the registrants internal
		control over financial reporting that occurred during the registrants
		most recent fiscal quarter (the registrants fourth fiscal quarter in the
		case of an annual report) that has materially affected, or is reasonably likely
		to materially affect, the registrants internal control over financial
		reporting; and

5.

The registrants other certifying officer and I have disclosed,
		based on our most recent evaluation of internal control over financial
		reporting, to the registrants auditors and the audit committee of the
		registrants board of directors (or persons performing the equivalent
		functions):

a)

All significant deficiencies and material weaknesses in the design or
		operation of internal control over financial reporting which are reasonably
		likely to adversely affect the registrants ability to record, process,
		summarize and report financial information; and

b)

Any fraud, whether or not material, that involves management or other
		employees who have a significant role in the registrants internal control
		over financial reporting.



|                                                              
|--------------------------------------------------------------
|                                                              
|Date: August 15, 2007                                         
|/s/ David Aviezer                                             
|                                                              
|David Aviezer, Ph.D.
			 President and Chief Executive Officer